It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Plant-produced pharmaceuticals have been consistently controversial. The idea of producing pharmaceutical proteins in plants spans pharmaceutical production where biotechnology is less controversial for the public, and agricultural biotechnology where biotechnology where it has been more controversial. But the controversy seems to have abated since 2003-2006 when it hit a peak. In the early 2000’s there were a larger number of new products in stage I clinical trials. This was perhaps spillover from investments made during the life sciences phase. As the first group of produces got weeded out in clinical trials, the numbers became less threatening. Publication of new USDA regulations on the handling of non-food genetically modified plants may have lessened fears about mishandling. The draft guidance for Field Testing of Plants Engineered To Produce Pharmaceutical and Industrial Compounds was published in 2003.
originally posted by: Bluntone22
a reply to: Lumenari
How much money would you invest with no chance of return?
$1 million?
$100 million?
originally posted by: Lumenari
originally posted by: Bluntone22
a reply to: Lumenari
How much money would you invest with no chance of return?
$1 million?
$100 million?
If something has been proven to cure most types of cancer but you can't make money off it, how much would you pay to silence the research if you had a product that you spent $100 million on developing a synthetic version of that isn't as effective but you could patent it so you are the only supplier?
Or... why not share the information about the plant so more people could live?
Oh right... we're back to how much money you could make for a less effective alternative if you just shut up the people who point out that a plant-based pharmaceutical works better.
I understand the business side of it that you are pointing out.
"Treating" cancer is a multi-billion dollar business, after all.
"Curing" cancer with something the patient could just grow?
Where is the profit in that?
So why bother?
Stacy Erholtz battled multiple myeloma for 10 years, undergoing multiple chemotherapies and two stem-cell transplants only to relapse each time. Just as she ran out of treatment options, her doctors at Mayo Clinic suggested a radical treatment, a single high dose of the measles virus.